Drug Trial Radar · NCT07854847
Study Interchangeability Hep-B Vaccine Administered at Birth Dose
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Feb 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- PT Bio FarmaIndustry
- Sponsor type
- Industry
- Collaborators
- Universitas Padjadjaran
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 days, up to 3 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.
Conditions
- Vaccination Adverse Event
- Immunogenicity, Vaccine
Interventions
In-house Hepatitis B VaccineBiological
0,5 ml In-House Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh
Registered Hepatitis B VaccineBiological
0,5 ml Registered Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh
Primary outcomes
What the sponsor says the trial is designed to measure.
- Protectivity of primary series In-House Recombinant Hepatitis B vaccineTime frame: 28 days after administration of third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.